143 related articles for article (PubMed ID: 9352324)
21. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
Trifilio SM; Rademaker AW; Newman D; Coyle K; Carlson-Leuer K; Mehta J; Altman J; Frankfurt O; Tallman MS
Leuk Res; 2012 Apr; 36(4):394-6. PubMed ID: 22172465
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
23. Etoposide in acute leukemia. Past experience and future perspectives.
Ho AD; Brado B; Haas R; Hunstein W
Cancer; 1991 Jan; 67(1 Suppl):281-4. PubMed ID: 1984828
[TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed acute myeloid leukaemia.
Kell J
Rev Recent Clin Trials; 2006 May; 1(2):103-11. PubMed ID: 18473961
[TBL] [Abstract][Full Text] [Related]
25. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
[TBL] [Abstract][Full Text] [Related]
26. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
Link H; Freund M; Diedrich H; Wilke H; Austein J; Henke M; Wandt H; Fackler-Schwalbe E; Schlimok G; Hoffmann R
Haematol Blood Transfus; 1990; 33():322-5. PubMed ID: 2182426
[TBL] [Abstract][Full Text] [Related]
28. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Davis RB; Holland JF; Martelo O; Schiffer CA
Am J Clin Oncol; 1990 Dec; 13(6):516-9. PubMed ID: 2239806
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
[TBL] [Abstract][Full Text] [Related]
30. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.
Gruber A; Liliemark E; Tidefelt U; Paul C; Björkholm M; Peterson C; Liliemark J
Leuk Res; 1995 Oct; 19(10):757-61. PubMed ID: 7500654
[TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
Ho AD; Lipp T; Ehninger G; Meyer P; Rückle H; Steinke B; Kaboth W; Körbling M
Onkologie; 1986 Jun; 9(3):148-50. PubMed ID: 3528961
[TBL] [Abstract][Full Text] [Related]
34. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
35. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
36. [Mitoxantrone, etoposide, and cytarabine combination therapy for acute myeloid leukemia patients failing to achieve a complete remission after induction chemotherapy: a single-center experience].
Morita-Fujita M; Yabushita T; Shimomura Y; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Ishikawa T
Rinsho Ketsueki; 2018; 59(7):858-864. PubMed ID: 30078794
[TBL] [Abstract][Full Text] [Related]
37. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
Walters RS; Kantarjian HM; Keating MJ; Plunkett WK; Estey EH; Andersson B; Beran M; McCredie KB; Freireich EJ
Cancer; 1988 Aug; 62(4):677-82. PubMed ID: 3165047
[TBL] [Abstract][Full Text] [Related]
39. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
40. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
O'Brien S; Kantarjian H; Estey E; Koller C; Beran M; McCredie K; Keating M
Cancer; 1991 Aug; 68(4):691-4. PubMed ID: 1855168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
